Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Brendon E. Cook"'
Autor:
Charles A. Maitz, Samantha Delaney, Brendon E. Cook, Afaf R. Genady, Rebecca Hoerres, Marina Kuchuk, Georgios Makris, John F. Valliant, Saman Sadeghi, Jason S. Lewis, Heather M. Hennkens, Jeffrey N. Bryan, Brian M. Zeglis
Publikováno v:
Mol Pharm
The last decade has played witness to the creation of a highly effective approach to in vivo pretargeting based on the inverse electron demand Diels-Alder (IEDDA) click ligation between tetrazine (Tz) and trans-cyclooctene (TCO). Despite the steady p
Autor:
Brendon E. Cook, Jonathan Archbold, Khaled Nasr, Sara Girmay, Stanley I. Goldstein, Pei Li, Sivaraman Dandapani, Nathan E. Genung, Sac-Pham Tang, Stuart McClusky, Christophe Plisson, Megan E. Afetian, Chrissa A. Dwyer, Michael Fazio, William J. Drury, Frank Rigo, Laurent Martarello, Maciej Kaliszczak
Publikováno v:
Molecular imaging and biology. 24(6)
The treatment of complex neurological diseases often requires the administration of large therapeutic drugs, such as antisense oligonucleotide (ASO), by lumbar puncture into the intrathecal space in order to bypass the blood-brain barrier. Despite th
Autor:
Jordan M. White, Brendon E. Cook, Nerissa T. Viola, Outi Keinänen, Heather M. Gibson, Brian M. Zeglis
Publikováno v:
Mol Pharm
The N-linked biantennary glycans on the heavy chain of immunoglobulin G (IgG) antibodies (mAbs) are instrumental in the recognition of the Fc region by Fc-gamma receptors (FcγR). In the case of full-length mAb-based imaging tracers targeting immune
Autor:
Kathryn M. Tully, Jason S. Lewis, Kimberly Fung, Outi Keinänen, Rosemery Membreno, Brian M. Zeglis, Brendon E. Cook
Publikováno v:
Molecular Pharmaceutics. 16:2259-2263
Pretargeted radioimmunotherapy (PRIT) based on the inverse electron demand Diels–Alder reaction has shown promise in murine models of disease, yet the radiation dosimetry of this approach must be optimized to make it a viable clinical option. To th
Publikováno v:
Journal of Nuclear Medicine. 58:1553-1559
In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their pharmacokinetic limitations. The core premise of pretargeting
Publikováno v:
Dalton Trans
Metallic radionuclides have been instrumental in the field of nuclear imaging for over half a century. While recent years have played witness to a dramatic rise in the use of radiometals as labels for chelator-bearing biomolecules, imaging agents bas
Publikováno v:
Journal of Visualized Experiments.
While radioimmunotherapy (RIT) is a promising approach for the treatment of cancer, the long pharmacokinetic half-life of radiolabeled antibodies can result in high radiation doses to healthy tissues. Perhaps not surprisingly, several different strat
The development of immunoconjugates requires a careful balance between preserving the functionality of the antibody and modifying the immunoglobulin with the desired cargo. Herein, we describe the synthesis, development, in vivo evaluation of a novel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc7b3ad77ea3e4b72416f5026e4f2667
https://europepmc.org/articles/PMC6432625/
https://europepmc.org/articles/PMC6432625/
Pretargeted radioimmunotherapy (PRIT) based on the inverse electron demand Diels-Alder (IEDDA) reaction between tetrazine (Tz) and trans-cyclooctene (TCO) represents a promising strategy for leveraging the affinity and specificity of antibodies witho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1fda51c4cf3c685149196f28d3a956d
https://europepmc.org/articles/PMC6467224/
https://europepmc.org/articles/PMC6467224/
Publikováno v:
Nuclear Medicine and Biology. :S17-S18